The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 134, Issue 2, 2007, Pages 335-341

  Momin, Aziz ^a   Melikian, Narbeh ^a   Wheatcroft, Stephen B ^b   Grieve, David ^a   John, Lindsay C ^c   El Gamel, Ahmad ^c   Marrinan, Michael T ^c   Desai, Jatin B ^c   Driver, Catherine ^c   Sherwood, Roy ^c   Shah, Ajay M ^a   Kearney, Mark T ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS; SAPHENOUS VEIN; SIMVASTATIN; VASCULAR PATENCY;

EID: 34447625706     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.12.064     Document Type: Article

References (30)

1. Landmesser U., Hornig B., and Drexler H. Endothelial function: a critical determinant in atherosclerosis?. Circulation 109 Suppl II (2003) II27-II33
2. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 Suppl (2004) II2-II10
3. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
4. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifret P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108 (2003) 512-515
5. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
6. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
7. Plenge J.K., Hernandez T.L., Weil K.M., Poirer P., Grunwald G.K., Marcovina S.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
8. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Deveraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
9. Lohman T., Roche A., Martorel R., and The Airlie (VA) Consensus Conference. Standardisation of anthropomorphic measurements (1988), Human Kinetics, Champaign, IL 39-80
10. MRC/BHF Heart Protection Study. Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
11. Momin A.U., Melikian N.., Shah A.M., Grieve D.J., Wheatcroft S.B., John L., et al. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J. (2006) [Epub ahead of print]
12. Sullivan D.R., Marwick T.H., and Freedman S.B. A new method of scoring angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 119 (1990) 1262-1267
13. Raja S.G., Haider Z., Ahmad M., and Zaman H. Saphenous vein grafts: to use or not to use?. Heart Lung Circ. 13 (2004) 150-156
14. Soyombo A.A., Angelini G.D., and Newby A.C. Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J Thorac Cardiovasc Surg. 109 (1995) 2-12
15. Tanner F.C., Largiader T., Greutert H., Yang Z., and Luscher T.F. Nitric oxide synthase gene transfer inhibits biological features of bypass graft disease in the human saphenous vein. J Thorac Cardiovasc Surg. 127 (2004) 20-26
16. Guzik T.J., West N.E., Pillai R., Taggart D.P., and Channon K.M. Nitric oxide modulates superoxide release and peroxnitrite formation in human blood vessels. Hypertension 39 (2002) 1088-1094
17. Manchio J.V., Gu J., Romar L., Brown J., Gammie J., Pierson III R.N., et al. Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. Ann Thorac Surg. 79 (2005) 1991-1998
18. Brunner H., Cockcroft J.R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al., Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 23 (2005) 233-246
19. Mancini G.B. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med. 23 (2000) 144-161
20. Larose E., and Ganz P. Statins and endothelial dysfunction. Semin Vasc Med. 4 (2004) 333-346
21. Fichtlscherer S., Breuer S., Schachinger V., Dimmeler S., and Zeiher A.M. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J. 25 (2004) 1412-1418
22. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 350 (2004) 1495-1504
23. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 352 (2005) 20-28
24. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al., Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med. 352 (2005) 29-38
25. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
26. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347 (2002) 1557-1565
27. Zieske A.W., Tracy R.P., McMahan A., Herderick E.E., Homma S., Malcom G.T., et al., Pathobiological Determinants of Atherosclerosis in Youth Research Group. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 25 (2005) 1237-1243
28. Jabs W.J., Theissing E., Nitschke M., Bechtel J.F., Duchrow M., Mohamed S., et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 108 (2003) 1428-1431
29. Inoue T., Kato T., Uchida T., Sakuma M., Nakajima A., Shibazaki M., et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 46 (2005) 239-245
30. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684